Company Overview of Coherus Biosciences Inc
Coherus Biosciences Inc., a biopharmaceutical company, engages in the development, manufacture, and commercialization of biologic therapeutics. The company develops biologic medicines primarily for the treatment of oncology and inflammatory diseases. It serves customers globally. The company has a strategic collaboration with Daiichi Sankyo. Coherus Biosciences Inc. was founded in 2010 and is based in Redwood City, California.
201 Redwood Shores Parkway
Redwood City, CA 94065
Founded in 2010
Key Executives for Coherus Biosciences Inc
Senior Vice President of Inflammatory Diseases
Senior Vice President of Oncology
Compensation as of Fiscal Year 2014.
Coherus Biosciences Inc Key Developments
Coherus BioSciences, Inc. Announces CHS-1420 (Investigational Adalimumab Biosimilar) Meets Primary Endpoint in Pivotal Pharmacokinetic Clinical Study
Aug 14 14
Coherus BioSciences Inc. announced that CHS-1420, its proposed biosimilar of adalimumab (Humira(R)), met the primary endpoint in a pivotal clinical pharmacokinetic (PK) similarity study that compared CHS-1420 to Humira(R) in healthy subjects. The parallel-group, single-dose study met the criteria for clinical PK similarity on all three required, prospectively defined, PK endpoints: maximum serum concentration (C(max)), area under the time-concentration curve from first to last time point measured (AUC(0-t)), and area under the time-concentration curve from first time point extrapolated to infinity (AUC(0-inf)), with all three geometric mean ratios fully within the 90% confidence interval from 80% to 125%. Both agents were well tolerated and there were no differential safety findings observed between the two agents in this study.
Coherus Announces Initiation Of Phase 3 Trial Of CHS-0214 in Chronic Plaque Psoriasis (RaPsOdy)
Jul 16 14
Coherus BioSciences Inc. announced the start of its Phase 3 trial of CHS-0214, a proposed biosimilar of etanercept (Enbrel(R)), in chronic plaque psoriasis (the RaPsOdy trial). This announcement follows the recent initiation of a Phase 3 trial of CHS-0214 in rheumatoid arthritis. The Phase 3 psoriasis trial is a 48-week, randomized, double-blind, active-control, parallel-group, multicenter, global study in subjects with active, chronic plaque psoriasis who are naïve to systemic biologic therapy. The study will seek to demonstrate biosimilarity between CHS-0214 and Enbrel(R) in terms of efficacy, safety and immunogenicity. The primary efficacy endpoint is based on percent improvement in the Psoriasis Area and Severity Index (PASI) at 12 weeks.
Coherus BioSciences, Inc. Appoints V. Bryan Lawlis to Board of Directors
Jul 9 14
Coherus BioSciences Inc. announced the appointment of V. Bryan Lawlis to its Board of Directors.
Similar Private Companies By Industry
Recent Private Companies Transactions